Recent Updates
Recently added Catalysts
MDXG Neutral Sentiment

forth in the forward-looking statements. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement. About MIMEDX MIMEDX i

Key Takeaway: MIMEDX has announced a major restructuring aimed at improving profitability by reducing annual operating expenses by approximately $40 million. This organizational change comes as the company faces slow recovery in its Wound Care business following a reduction in Medicare reimbursements. The position of Chief Operating Officer has been eliminated as part of these changes, indicating a significant shift in the company's operational structure. Leadership change and adjustments are expected to be discussed in an upcoming quarterly conference call.
Price reaction · baseline $3.88 (2026-04-15 close) · hit after-hours · 1 other MDXG headline(s) in the window, move may be shared
day 0 close
-11.6%
day 1
-12%
day 3 · peak
-17.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • MIMEDX has a leading portfolio for wound care and surgical sectors.
  • Company's vision focuses on innovation to restore quality of life.
  • Surgical business continues to flourish despite restructuring efforts.

CONCERNS & RISKS

  • Wound care business is recovering slowly from Medicare reimbursement reduction.
  • A one-time restructuring charge of approximately $4 million is expected.
  • The elimination of the COO position indicates significant restructuring.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~40 mo
Low dilution risk
Lead asset
Micronized DHACM
Phase 3 · Tendonitis;Achilles

Full Press Release Details

Actual results may differ materially from those set EXHIBIT 99.1 forth in the forward-looking statements. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement. About MIMEDX MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare.
Additional forward- looking statements may be identified by words such as "believe," "expect," "may," "plan," "goal," "outlook," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements.
Capper. The Company plans to provide additional commentary around the first quarter of 2026 operating and financial results and the impact of this reorganization during its quarterly conference call in late April. Forward Looking Statements This press release includes forward-looking statements, including statements regarding our expectations regarding the impact of our cost reduction initiatives and reimbursement changes.
Based on first quarter market behavior, it is clear the transition is happening at a more sluggish pace, and we must now make the requisite adjustments to our cost structure to ensure the future profitability of the business. As such, we have taken steps to reduce our annual operating expenses across the enterprise by approximately $40 million. We expect a one-time restructuring charge of approximately $4 million during the second quarter of 2026 associated with these changes," concluded Mr.
Capper continued, "This leadership change comes as part of a broader restructuring and cost savings initiative at MIMEDX. Over the last few months, we have conducted a detailed review of our business and supporting corporate structure. While our Surgical business continues to flourish and warrants additional investments, our Wound Care business, along with the broader market, is recovering from the January 1st Medicare reimbursement reduction at a very slow rate." "As we entered the new year, we kept the organization resourced in the event of a rapid recovery in the Wound market.
"Ricci joined the Company at a pivotal time in the organization's history and successfully navigated us through several regulatory audits and product launches, all while helping us scale operations in support of our long-term growth aspirations. We are deeply grateful for Ricci's commitment to the organization, and we wish her the very best in all future endeavors." Mr.
As part of these changes, the position of Chief Operating Officer, held by Ricci Whitlow, has been eliminated. "On behalf of the Board and management team, I want to thank Ricci for her innumerable contributions to MIMEDX and her exceptional leadership in helping to build and scale our operations," stated Joseph H. Capper, MIMEDX Chief Executive Officer.
The Company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com. Contact: Matt Notarianni Investor Relations 470-304-7291 mnotarianni@mimedx.com

Frequently Asked Questions

What is MIMEDX known for?

MIMEDX is a leader in helping humans heal, specializing in chronic and hard-to-heal wounds.

What does MIMEDX focus on?

MIMEDX provides products for wound care, burns, and surgical applications in healthcare.

What impact do cost reductions have on MIMEDX?

MIMEDX expects to reduce annual expenses by approximately $40 million for profitability.

How is MIMEDX addressing market changes?

MIMEDX is adjusting its cost structure due to slow recovery from reimbursement reductions.

Who is leading MIMEDX after recent changes?

Joseph H. Capper is the CEO of MIMEDX following the elimination of Ricci Whitlow's position.

Last updated: Apr 16, 2026